Analysts: Allergan’s Phase II Trial Released Early and 3 More Research Notes to Browse

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Allergan (NYSE:AGN): BMO Capital points out that Stage 3 of Allergan’s phase II trial for its anti-VEGF DARPin product was released on sooner than expected. BMO sees this as a positive for the company and has an Outperform rating on the stock with a $118 price target.


More Articles About:

To contact the reporter on this story: To contact the editor responsible for this story:

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business